JP7222987B2 - 抗ｒｏｒ１抗体とその作製及び使用方法 - Google Patents

抗ｒｏｒ１抗体とその作製及び使用方法 Download PDF

Info

Publication number
JP7222987B2
JP7222987B2 JP2020520426A JP2020520426A JP7222987B2 JP 7222987 B2 JP7222987 B2 JP 7222987B2 JP 2020520426 A JP2020520426 A JP 2020520426A JP 2020520426 A JP2020520426 A JP 2020520426A JP 7222987 B2 JP7222987 B2 JP 7222987B2
Authority
JP
Japan
Prior art keywords
seq
antigen
cancer
acid sequence
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020520426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529863A5 (https=
JP2020529863A (ja
JPWO2019005636A5 (https=
Inventor
オーレ オルセン，
フィル タン，
ドン シア，
デイビッド ジェリーマン，
ブライアン コヴァセヴィチ，
ビル ブレイディ，
ブレア レンショー，
ゼレン ガオ，
イ ツー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Systimmune Inc
Original Assignee
Systimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc filed Critical Systimmune Inc
Publication of JP2020529863A publication Critical patent/JP2020529863A/ja
Publication of JP2020529863A5 publication Critical patent/JP2020529863A5/ja
Publication of JPWO2019005636A5 publication Critical patent/JPWO2019005636A5/ja
Priority to JP2023015342A priority Critical patent/JP7464764B2/ja
Application granted granted Critical
Publication of JP7222987B2 publication Critical patent/JP7222987B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020520426A 2017-06-25 2018-06-22 抗ｒｏｒ１抗体とその作製及び使用方法 Active JP7222987B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023015342A JP7464764B2 (ja) 2017-06-25 2023-02-03 抗ｒｏｒ１抗体とその作製及び使用方法

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201762524554P 2017-06-25 2017-06-25
US201762524557P 2017-06-25 2017-06-25
US201762524558P 2017-06-25 2017-06-25
US62/524,558 2017-06-25
US62/524,554 2017-06-25
US62/524,557 2017-06-25
US201762545603P 2017-08-15 2017-08-15
US62/545,603 2017-08-15
US201762551032P 2017-08-28 2017-08-28
US201762551065P 2017-08-28 2017-08-28
US201762551035P 2017-08-28 2017-08-28
US62/551,065 2017-08-28
US62/551,035 2017-08-28
US62/551,032 2017-08-28
PCT/US2018/039152 WO2019005636A2 (en) 2017-06-25 2018-06-22 ANTI-ROR1 ANTIBODIES AND METHODS OF PREPARATION AND USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023015342A Division JP7464764B2 (ja) 2017-06-25 2023-02-03 抗ｒｏｒ１抗体とその作製及び使用方法

Publications (4)

Publication Number Publication Date
JP2020529863A JP2020529863A (ja) 2020-10-15
JP2020529863A5 JP2020529863A5 (https=) 2022-01-17
JPWO2019005636A5 JPWO2019005636A5 (https=) 2022-01-17
JP7222987B2 true JP7222987B2 (ja) 2023-02-15

Family

ID=64742585

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020520426A Active JP7222987B2 (ja) 2017-06-25 2018-06-22 抗ｒｏｒ１抗体とその作製及び使用方法
JP2020520428A Active JP7323513B2 (ja) 2017-06-25 2018-06-22 抗４－１ｂｂ抗体とその作製及び使用方法
JP2023015342A Active JP7464764B2 (ja) 2017-06-25 2023-02-03 抗ｒｏｒ１抗体とその作製及び使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020520428A Active JP7323513B2 (ja) 2017-06-25 2018-06-22 抗４－１ｂｂ抗体とその作製及び使用方法
JP2023015342A Active JP7464764B2 (ja) 2017-06-25 2023-02-03 抗ｒｏｒ１抗体とその作製及び使用方法

Country Status (5)

Country Link
US (2) US11987635B2 (https=)
EP (2) EP3645742B1 (https=)
JP (3) JP7222987B2 (https=)
CN (7) CN116789832A (https=)
WO (2) WO2019005636A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
CN115485298A (zh) * 2020-01-30 2022-12-16 英克特诺治疗公司 用于治疗癌症的egfr抑制剂和ror1抑制剂的组合
AU2021225920A1 (en) * 2020-02-28 2022-09-15 Shanghai Henlius Biotech, Inc. Anti-CD137 construct and use thereof
CN111499746B (zh) * 2020-04-28 2020-11-24 优睿赛思(武汉)生物科技有限公司 一种针对人白介素-2的高亲和力兔单克隆抗体及其应用
EP4188430A4 (en) * 2020-07-28 2024-11-06 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use
TWI818308B (zh) * 2020-09-03 2023-10-11 大陸商和鉑醫藥（上海）有限責任公司 標靶ｒｏｒ１的抗體或其抗原結合片段及製備方法和應用
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CN115433277A (zh) * 2021-06-05 2022-12-06 苏州缔码生物科技有限公司 抗cd38兔重组单克隆抗体的制备及应用
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
CN116333139B (zh) * 2021-12-22 2026-02-27 上海复旦张江生物医药股份有限公司 一种抗fda0128抗体、其制备方法和应用
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
CN118745226B (zh) * 2023-06-07 2026-02-17 浙江博锐生物制药有限公司 抗ror1抗体及其应用
CN117467004B (zh) * 2023-10-09 2024-06-21 武汉爱博泰克生物科技有限公司 抗人钙网膜蛋白的兔单克隆抗体及其应用
WO2025106600A2 (en) * 2023-11-15 2025-05-22 Systimmune, Inc. Anti-dll3 antibody and method of making and using thereof
CN117624355B (zh) * 2023-11-30 2024-05-14 无锡傲锐东源生物科技有限公司 一种抗人乙酰化tau274兔单克隆抗体及其应用
CN117736330B (zh) * 2024-01-24 2024-05-17 上海沙砾生物科技有限公司 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
CN118930648B (zh) * 2024-08-22 2025-02-28 武汉爱博泰克生物科技有限公司 抗人pax8蛋白的兔单克隆抗体、抗体偶联物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251642A1 (en) 2010-12-01 2013-09-26 The United States of America, as represented by the secretary, Department of Heath and Human Servi Chimeric rabbit/human ror1 antibodies
JP2015532644A (ja) 2012-08-24 2015-11-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU2002364935A1 (en) * 2001-10-09 2003-06-23 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
AR046094A1 (es) * 2003-10-10 2005-11-23 Bristol Myers Squibb Co Anticuerpos completamente humanos contra 4-1bb humano
US20080152655A1 (en) * 2004-09-08 2008-06-26 The Ohio State University Research Foundation Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies
AU2015252014B2 (en) * 2009-04-23 2017-03-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
PT2614082T (pt) * 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
DK3252076T3 (da) * 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
HRP20201595T1 (hr) * 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
US9139649B2 (en) * 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
SG11201704741PA (en) * 2014-12-22 2017-07-28 Systimmune Inc Bispecific tetravalent antibodies and methods of makiing and using thereof
CN104817642B (zh) * 2015-05-04 2018-03-27 北京百普赛斯生物科技有限公司 抗人ror1单克隆抗体及其制备方法与应用
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251642A1 (en) 2010-12-01 2013-09-26 The United States of America, as represented by the secretary, Department of Heath and Human Servi Chimeric rabbit/human ror1 antibodies
JP2015532644A (ja) 2012-08-24 2015-11-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clin. Cancer Res.，2017年06月15日，Vol.23, No.12，pp.3061-3071

Also Published As

Publication number Publication date
CN116731180A (zh) 2023-09-12
CN110869389A (zh) 2020-03-06
JP7323513B2 (ja) 2023-08-08
JP7464764B2 (ja) 2024-04-09
US11987635B2 (en) 2024-05-21
US11518815B2 (en) 2022-12-06
US20210188989A1 (en) 2021-06-24
CN116731179A (zh) 2023-09-12
CN116789832A (zh) 2023-09-22
CN110869389B (zh) 2023-07-28
EP3645742A2 (en) 2020-05-06
US20210277109A1 (en) 2021-09-09
WO2019005636A2 (en) 2019-01-03
JP2020529863A (ja) 2020-10-15
EP3645741A4 (en) 2021-08-25
WO2019005638A2 (en) 2019-01-03
EP3645741A2 (en) 2020-05-06
JP2023065391A (ja) 2023-05-12
EP3645742B1 (en) 2026-04-29
CN110799539B (zh) 2023-08-15
CN116925227A (zh) 2023-10-24
JP2020531043A (ja) 2020-11-05
CN116769035A (zh) 2023-09-19
CN110799539A (zh) 2020-02-14
EP3645742A4 (en) 2021-07-14

Similar Documents

Publication Publication Date Title
JP7464764B2 (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
JP7356970B2 (ja) 多重特異性抗体とその作製及び使用方法
JP7490109B2 (ja) 抗ｐｄ－１抗体とその作製及び使用方法
JP7164596B2 (ja) 抗ｃｄ３抗体とその作製及び使用方法
JP7610680B2 (ja) 抗ｐｄ－ｌ１抗体とその作製及び使用方法
CN116041530A (zh) 多特异性抗体及其制备和使用方法
KR20220133884A (ko) 항-mdr1 항체 및 이의 용도
US20250376531A9 (en) Anti-4-1bb antibodies and methods of making and using thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230203

R150 Certificate of patent or registration of utility model

Ref document number: 7222987

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350